Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 113 publications.
Skip to main content
Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg E, Makari D, Candrilli SD, Goyal RK, Rugo HS. Overall survival with palbociclib and aromatase inhibitor versus aromatase inhibitor alone in older patients with HR+/HER2− metastatic breast cancer. Cancer Med. 2025 Apr;14(7):e70719. doi: 10.1002/cam4.70719
Shadman M, Roeker L, Pinilla-Ibarz J, Srivastava B, Karve S, Krigsfeld GS, Franceschini E, Saifan C, Karanth S, Goyal RK, Rombi J, Stephens DM. Association between dose reduction and duration of therapy in patients receiving ibrutinib or acalabrutinib for chronic lymphocytic leukemia: a medical chart review study. Poster presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2024. San Diego, California.
Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, Makari D, Goyal RK. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024 Nov;208(2):223-35. doi: 10.1007/s10549-024-07469-6
Mody FV, Goyal RK, Ajmera M, Davis KL, Amin AN. Exploring the association between heart rate control and rehospitalization: a real-world analysis of patients hospitalized with heart failure with reduced ejection fraction. Drugs Real World Outcomes. 2024 Sep;11(3):501-11. doi: 10.1007/s40801-024-00436-z
Campelo MD, Yucel A, Goyal RK, Glassberg MB, Esterberg L, Rombi J, Davis KL, Jimenez M, Miteva D, Germing U. Luspatercept utilization patterns in lower-risk myelodysplastic syndrome (LR-MDS): findings from a multinational medical record review study. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Goyal RK, Candrilli SD, Abughosh S, Chen H, Holmes HM, Johnson ML. Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer. Cancers. 2024 Jun 7;16(12):2168. doi: 10.3390/cancers16122168
Brufsky A, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg L, Makari D, Candrilli S, Goyal R, Rugo H. Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: a SEER-Medicare analysis. Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2024. Chicago, IL.
Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-kinase inhibitor treatment for metastatic breast cancer. Breast Cancer Res Treat. 2024 May;205(1):201-10. doi: 10.1007/s10549-023-07080-1
Diez-Campelo M, Yucel A, Goyal RK, Parikh RC, Esterberg E, Jimenez M, Sluga-O'Callaghan M, Miteva D, Xiao H, Germing U. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228
Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024;20(22):1553-63. doi: 10.2217/fon-2023-1064
Goyal RK, Candrilli SD, Abughosh SM, Chen H, Holmes HM, Johnson ML. Social Determinants of Health (SDoH) and other predictors in treatment initiation with CDK4/6 inhibitors in Medicare patients with HR+/HER2– Metastatic Breast Cancer (MBC). Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S286. doi: 10.1016/j.jval.2023.09.1502
Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025
Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Brufsky A, Kwan ML, Sandin R, Karanth S, Makari D, Stergiopoulos S, Goyal R. Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019. Poster presented at the ESMO Congress 2023; October 21, 2023. Madrid, Spain.
Goyal RK, Frugier G, Rombi J, Esterberg L, Davis KL, Hlavacek P, Ren J, Schepart A, Aydin D, DeBonaventura M. Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: a real-world observational chart review study. Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL.
Gohil S, Johnson ML, Goyal R. Impact of a cancer diagnosis on non-cancer chronic disease medication adherence - a systematic literature review. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S197. doi: 10.1016/j.jval.2023.03.1064
Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study. Cancer. 2023 Apr 1;129(7):1051-63. doi: 10.1002/cncr.34675
Goyal RK, Holmes HM, Chen H, Abughosh S, Candrilli SD, Johnson ML. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb;198(1):159-66. doi: 10.1007/s10549-022-06845-4
Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Derrien Ansquer V, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-28. doi: 10.2217/fon-2022-1133
Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.
Goyal RK, Zhang J, Davis KL, Kaufman PA. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior PI3K inhibitor therapy for metastatic breast cancer. Poster presented at the 2022 San Antonio Breast Cancer Symposium (SABCS); December 6, 2022. San Antonio, TX.
Hudson KE, Arnold Egloff SA, Goyal RK, Cai B, Caro N, Frost M, Darrien Ansquer V, Davis KL. Real-world assessment of clinical outcomes associated with immunotherapy and chemotherapy in patients with non–small cell lung cancer with brain metastases and MET exon 14 skipping mutations treated in US community centers. Poster presented at the 2022 North America Conference on Lung Cancer; September 25, 2022. Chicago, IL.
Diez-Campelo M, Yucel A, Goyal R, Parikh R, Dhuliawala S, Jimenez M, Sluga-O'Callaghan M, Hughes C, Tang D, Germing U. Systemic therapy utilization and hematologic outcomes in lower-risk myelodysplastic syndromes (LR-MDS): findings from a real-world medical record review study in the US, UK, and Europe (EU). Poster presented at the 2022 European Hematology Association Hybrid Congress; June 10, 2022. Vienna, Austria.
Paik PK, Goyal RK, Cai B, Price M, Davis K, Derrien Ansquer V, Caro N, Saliba TR. Real-world assessment of clinical outcomes in NSCLC patients with MET exon 14 skipping mutation and brain metastases (BM) treated with capmatinib. Poster presented at the ASCO 2022 Annual Meeting; June 2022. Chicago, IL. [abstract] J Clin Oncol. 2022 Jun 2; 40(16_suppl):e21171. doi: 10.1200/JCO.2022.40.16_suppl.e21171
Ardeshirrouhanifard S, An H, Goyal RK, Raji MA, Segal JB, Alexander GC, Mehta HB. Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016. Pharmacotherapy. 2022 May;42(5):375-86. doi: 10.1002/phar.2679
Goyal RK, Zhang J, Dhuliawala S, Slug-O'Callaghan M, Kaufman PA. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior Immunotherapy (IO) or Antibody-Drug Conjugate (ADC) for metastatic breast cancer. Poster presented at the 39th Annual Miami Breast Cancer Conference; March 3, 2022. Miami Beach, FL.
Germing U, Goyal RK, Yucel A, Parikh RC, Jimenez M, Sluga-O'Callaghan M, Tang D, Hughes C, Diez-Campelo M. Real-world evidence on treatment utilization in lower-risk myelodysplastic syndromes: findings from a medical record review in the United States. Poster presented at the 63rd ASH Annual Meeting and Exposition; December 11, 2021. Atlanta, GA. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):4666. doi: 10.1182/blood-2021-145576
Ardeshirrouhanifard S, An H, Goyal RK, Segal J, Alexander GC, Mehta HB. Utilization patterns of direct oral anticoagulants in Medicare beneficiaries with cancer and non-valvular atrial fibrillation. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.
Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021 Jun;62(6):1325-34. doi: 10.1080/10428194.2021.1919662
Ardeshirrouhanifard S, An H, Goyal RK, Raji M, Segal J, Alexander GC, Mehta HB. Initiation and switching of direct oral anticoagulants among Medicare beneficiaries with cancer and atrial fibrillation. Poster presented at the 2021 American Heart Association, Epidemiology Scientific Session; May 2021. [abstract] Circulation. 2021 May 25; 143(Suppl 1):AP148.
Wu B, Morland K, Classi P, Sketch MR, Nelson A, Goyal RK, Davis KL, Oudiz R. Economic burden of patients with pulmonary arterial hypertension prior to initiation of treprostinil: a retrospective analysis of US claims. Poster presented at the ATS International 2021 Conference; May 14, 2021.
Hillmen P, Xie J, Yong A, Waweru C, Sorof TA, Goyal RK, Davis KL. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK. EJHaem. 2021 May;2(2):219-27. doi: 10.1002/jha2.174
Goyal RK, Nagar SP, Kabadi SM, Le H, Davis KL, Kaye JA. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the medicare population. Cancer Med. 2021 Apr;10(8):2690-702. doi: 10.1002/cam4.3855
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871
Obimah A, Goyal RK, Bhansali A, Sansgiry SS. Can intervention tools with better message framing lead to better intention: a case of chemoprevention for breast cancer. Poster presented at the 2020 AMCP (Conference cancelled); April 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr; 26(4-a):S89.
Xie J, Yong ASM, Waweru C, Sorof T-A, Goyal RK, Davis KL, Hillmen P. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the United Kingdom. Poster presented at the 2020 British Society for Haematology 60th Annual Scientific Meeting (Conference cancelled); April 2020. Birmingham, United Kingdom. [abstract] Br J Haematol. 2020 Apr; 189((Suppl.1)):221.
Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841
Goyal RK, Nagar SP, Kabadi SM, Davis KL, Le H, Kaye JA. Overall survival, adverse events, and economic burden in Medicare patients with chronic lymphocytic leukemia receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement 1):796. doi: 10.1182/blood-2019-122842
Xie J, Yong A, Waweru C, Sorof TA, Goyal RK, Davis KL, Fellows G, Hillmen P. Real-world treatment patterns and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib in the UK: a preliminary analysis. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):5885. doi: 10.1182/blood-2019-123025
Goyal RK, Cuyun Carter G, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, survival, and economic outcomes in Medicare-enrolled, older patients with HR+/HER2– metastatic breast cancer. Curr Med Res Opin. 2019 Oct;35(10):1699-710. doi: 10.1080/03007995.2019.1615422
Mazieres J, Ahn MJ, Chouaid C, Kron A, Wolf J, Goyal RK, Davis KL, Perrinjaquet M, Pham T, Knoll S. Genetic testing patterns, treatment characteristics, and overall survival in ALK-positive metastatic NSCLC patients treated with Ceritinib. Poster presented at the 2019 World Conference on Lung Cancer; September 8, 2019. Barcelona, Spain.
Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447
Kabadi SM, Goyal RK, Nagar SP, Kaye JA, Davis KL. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019 Jul;8(8):3803-10. doi: 10.1002/cam4.2268
Goyal RK, Nagar SP, Kabadi SM, Kaye JA, Seal B, Mato AR. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2019 Apr;60(4):955-63. doi: 10.1080/10428194.2018.1509320
Kabadi S, Goyal RK, Nagar SP, Kaye JA, Davis KL, Mato A. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2, 2018. San Diego, CA. [abstract] Blood. 2018 Nov 29; 132(Supplement 1):3557. doi: 10.1182/blood-2018-99-114735
Goyal R, Nagar S, Davis KL, Kaye JA. Time trends in frontline systemic therapy utilization for chronic lymphocytic leukemia in the United States. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 14, 2018. Barcelona, Spain.